LBLeslie A. Bruggeman

Leslie A. Bruggeman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Leslie A. Bruggeman has a total of 88 co-authors. Here are the top co-authors by number of shared publications:

  • John R. Sedor

    Department of Inflammation and Immunity, Cleveland Clinic, Cleveland, Ohio, USA; Department of Kidney Medicine, Cleveland Clinic, Cleveland, Ohio, USA; Department of Physiology and Biophysics, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA

    11 shared publications
  • Zhenzhen Wu

    Cleveland Clinic Research

    11 shared publications
  • John F. O’tOole

    Department of Inflammation and Immunity, Cleveland Clinic, Cleveland, Ohio, USA; Department of Kidney Medicine, Cleveland Clinic, Cleveland, Ohio, USA

    5 shared publications
  • John F. O’toole

    Departments of Inflammation and Immunity and Nephrology, Cleveland Clinic, Case Western Reserve University School of Medicine, Cleveland, USA

    5 shared publications
  • John R. Sedor

    Cleveland Clinic

    4 shared publications
  • Laura Barisoni

    Departments of Pathology and Medicine, Duke University, Durham, North Carolina, United States of America

    4 shared publications

Latest Publications

  • Differential regulation of basal and interferon-induced APOL1 gene expression in podocytes

    by Chunfa Huang, Zhenzhen Wu, Korey R. Bartolomeo, John F. O'TOole, John R. Sedor, Leslie A. Bruggeman

    APOL1 kidney disease is triggered by events that induce high levels of APOL1 expression. We show here that basal and induced APOL1 expression are regulated by different mechanisms, with induced expression largely dependent on interferon signaling. Treatment strategies may be developed to selectively block the pathogenic-induced levels of APOL1 while preserving basal levels that are known to provide beneficial functions against parasitic infections.

  • Open Access

    Impact of Apolipoprotein L1-Associated Pregnancy Complications on Kidney Disease Phenotypes in a HIV-Associated Nephropathy Mouse Model

    by Zhenzhen Wu, Timur Azhibekov, Chunfa Huang, Jane K. Nguyen, Korey R. Bartolomeo, Oliver Wessely, John F. O'TOole, John R. Sedor, Leslie A. Bruggeman

    Key Points: G0 coexpression did not improve CKD outcomes in a mouse model of HIV-associated nephropathy. Apolipoprotein L1 is expressed in the placenta, and risk variants are associated with preeclampsia, low birth weight, and reduced podocyte and glomerular density. Apolipoprotein L1 kidney disease risk may be mediated by apolipoprotein L1-associated birth complications negatively affecting kidney development. Background: Apolipoprotein L1 (APOL1) polymorphisms are a significant risk factor of kidney disease including HIV-associated nephropathy (HIVAN), but a comprehensive understanding of the pathogenic mechanism remains unclear. Methods: APOL1 transgenic models expressing APOL1 -G0 and the kidney disease risk–associated APOL1 -G1 variant were intercrossed with the Tg26 mouse model of HIVAN. Because all these transgenic models are hemizygous, crosses produced offspring of four genotypes: wild-type (WT) mice, APOL1 , Tg26, and dual transgenic mice expressing both APOL1 and Tg26 transgenes. Kidney function, pathology, and transgene expression patterns were examined in addition to podocyte and glomerular densities. Results: The WT and APOL1 G0 or G1 mice did not develop kidney disease, whereas Tg26 and dual transgenic mice developed severe kidney disease consistent with the Tg26 HIVAN phenotype. The outcome of the G1/Tg26 intercross was expressed during pregnancy with neonatal complications that included a preeclampsia-like phenotype, low fetal/placental weight ratios, low birth weights, and fewer dual transgenic offspring that survived to adulthood. Some adult offspring from the G1/Tg26 intercross also had reduced podocyte densities and fewer glomeruli. This included the WT and APOL1 -G1 mice, suggesting a systemic effect of the preeclampsia phenotype on the entire litter. The G0/Tg26 intercross also demonstrated kidney pathology and albuminuria similar to the G1/Tg26 intercross. Conclusions: Coexpression of G0 in the Tg26 mouse model was not protective against kidney disease. In addition, the G1-associated pregnancy complications, reduced podocyte and glomerular densities, suggest a second mechanism by which APOL1 risk variant expression may affect long-term kidney function.


  • Open Access

    Insidious APOL1 Kidney Disease: A Manifestation of APOL1-Associated Pregnancy Complications on Nephron Endowment?

    by Timur Azhibekov, Leslie A. Bruggeman

    The mechanism of kidney injury associated with apolipoprotein L1 (APOL1) risk variants has remained elusive. Complicating this issue is the broad clinical spectrum of APOL1 kidney disease, which has engendered speculation that this reflects multiple mechanisms of kidney injury. APOL1 kidney disease can be rapid in onset with heavy proteinuria, associated with viral infections and categorized pathologically as collapsing focal segmental glomerulosclerosis. Alternatively, APOL1 kidney disease also may present as an insidious, slowly progressive disease, with less proteinuria but losses in glomerular filtration rate and with varied pathology. In addition to APOL1 kidney disease, APOL1 risk variants are also associated with preeclampsia and other conditions related to placental insufficiency. The outcome of these APOL1-associated pregnancy complications frequently results in prematurity and low birth weight, both of which are known risk factors for hypertension and kidney disease later in life due to reduced nephron endowment. The significance of APOL1 risk variants on pregnancy complications that predispose to kidney disease should not be overlooked as a central mechanism of APOL1 kidney disease, especially the insidious forms, which are difficult to distinguish from the spectrum of kidney disease attributable to prematurity and low birth weight. If low nephron endowment is a causal mechanism behind some forms of APOL1 kidney disease, this may have an impact on clinical trials evaluating drugs directly inhibiting APOL1, since in these instances, ongoing APOL1 expression may not be driving podocyte loss and progressive kidney dysfunction.


  • Open Access

    APOL1 Genotype and HIV Infection: 20-Year Outcomes for CKD, Cardiovascular Disease, and Hypertension

    by Katherine K. Tassiopoulos, Kunling Wu, Zhenzhen Wu, Edgar T. Overton, Frank J. Palella, Christina Wyatt, Robert C. Kalayjian, Leslie A. Bruggeman


  • Open Access

    Cefazolin shifts the kidney microbiota to promote a lithogenic environment

    by Jose Agudelo, Xing Chen, Sromona D. Mukherjee, Jane K. Nguyen, Leslie A. Bruggeman, Aaron W. Miller

    Clinical studies of the urinary tract microbiome, termed urobiome, suggest a direct, antibiotic-dependent, impact of the urobiome on kidney physiology. However, evidence for kidney bacteria comes from indirect sources or infected tissue. Further, it is unclear how antibiotics impact kidney bacteria. Here we show direct evidence for the presence of bacteria in the kidneys, with microniches in nephrons. In murine kidneys, administration of cefazolin, a commonly used perioperative antibiotic, led to a loss of uroprotective Lactobacillus spp. and proliferation of Enterobacteriaceae (which includes many known uropathogens). This effect was dependent on treatment duration, with recovery post treatment. Uroprotective L. crispatus and a strain of stone-associated E. coli differentially influenced calcium oxalate (CaOx) crystallization through the incorporation of CaOx inhibitors or promoters, respectively. In humans, microbial signatures were identified in the kidney, with unique niches between the glomeruli and tubules, established through RNA sequencing analysis and direct imaging of two independent populations. Collectively, findings support the hypothesis that the kidneys harbor a stable and antibiotic-responsive microbiota that can influence CaOx lithogenesis. The presence of unique, age-dependent microbial signatures in the glomeruli and tubuli carry implications for non-infectious kidney diseases.


  • Open Access

    Local Inflammation But Not Kidney Cell Infection Associated with High APOL1 Expression in COVID-Associated Nephropathy

    by Jane K. Nguyen, Zhenzhen Wu, Jose Agudelo, Leal C. Herlitz, Aaron W. Miller, Leslie A. Bruggeman

    Key Points: In coronavirus disease-19 biopsies, detection of severe acute respiratory syndrome coronavirus 2 was rare with no evidence of viral replication, whereas autopsy tissue failed quality control. In patients with FSGS, apolipoprotein L1 expression differed by degree of immune cell infiltrates, with some podocytes exhibiting up to 18-fold higher expression. In COVAN, the predicted high induction of apolipoprotein L1 expression occurs in a pattern consistent with the stochastic nature of FSGS pathology.


  • Viral associations with kidney disease diagnosis and altered kidney metatranscriptome by kidney function

    by Changjin Hong, Felix Eichinger, Mohamed G. Atta, Michelle M. Estrella, Derek M. Fine, Michael J. Ross, Christina Wyatt, Tae Hyun Hwang, Matthias Kretzler, John R. Sedor, et al.


  • Essential role of Wtip in mouse development and maintenance of the glomerular filtration barrier

    by Sethu M. Madhavan, Martha Konieczkowski, Leslie A. Bruggeman, Megan DeWalt, Jane K. Nguyen, John F. O’tOole, John R. Sedor

    Wilms’ tumor interacting protein (Wtip) has been implicated in cell junction assembly and cell differentiation and interacts with proteins in the podocyte slit diaphragm, where it regulates podocyte phenotype. To define Wtip expression and function in the kidney, we created a Wtip-deleted mouse model using β-galactosidase-neomycin (β-geo) gene trap technology. Wtip gene trap mice were embryonic lethal, suggesting additional developmental roles outside kidney function. Using β-geo heterozygous and normal mice, Wtip expression was identified in the developing kidneys, heart, and eyes. In the kidney, expression was restricted to podocytes, which appeared initially at the capillary loop stage coinciding with terminal podocyte differentiation. Heterozygous mice had an expected lifespan and showed no evidence of proteinuria or glomerular pathology. However, heterozygous mice were more susceptible to glomerular injury than wild-type littermates and developed more significant and prolonged proteinuria in response to lipopolysaccharide or adriamycin. In normal human kidneys, WTIP expression patterns were consistent with observations in mice and were lost in glomeruli concurrent with loss of synaptopodin expression in disease. Mechanistically, we identified the Rho guanine nucleotide exchange factor 12 (ARHGEF12) as a binding partner for WTIP. ARHGEF12 was expressed in human podocytes and formed high-affinity interactions through their LIM- and PDZ-binding domains. Our findings suggest that Wtip is essential for early murine embryonic development and maintaining normal glomerular filtration barrier function, potentially regulating slit diaphragm and foot process function through Rho effector proteins. NEW & NOTEWORTHY This study characterized dynamic expression patterns of Wilms’ tumor interacting protein (Wtip) and demonstrates the novel role of Wtip in murine development and maintenance of the glomerular filtration barrier.